Essilor: Disclosure of Share Capital and Voting Rights Outstanding as of February 28, 2013

Mon Mar 4, 2013 12:11pm EST

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130304:nBw046361a

http://www.businesswire.com/news/home/20130304006361/en

(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1
and 223-16 of the General Regulations of the Autorité des Marchés Financiers) 
CHARENTON-LE-PONT, France--(Business Wire)--
Regulatory News: 

As of February 28, 2013, shares and voting rights outstanding of Essilor
(Paris:EI), the world leader in ophthalmic optics, broke down as follows:

                                                                                                                                        February 28, 2013               
 Shares outstanding                                                                                                                     214,875,909                     
 Exercisable voting rights                                                                                                              226,131,714                     
 Total voting rights, based on all outstanding shares, including shares stripped of their voting rights*                                230,826,378                     
 (*)Shares held by the Company, either in treasury or under the liquidity contract.                                                                                     


About Essilor

The world`s leading ophthalmic optics company, Essilor designs, manufactures and
markets a wide range of lenses to improve and protect eyesight. Its corporate
mission is to enable everyone around the world to access lenses that meet his or
her unique vision requirements. To support this mission, the Company allocates
around €150 million to research and development every year, in a commitment to
continuously bring new, more effective products to market. Essilor`s flagship
brands are Varilux®, Crizal®, Definity®, Xperio®, OptifogTM and Foster Grant®.
It also develops and markets equipment, instruments and services for eyecare
professionals.

Essilor reported consolidated revenue of approximately €5 billion in 2012 and
employs around 52,600 people in some 100 countries. It operates 22 plants, more
than 400 prescription laboratories and edging facilities, as well as several
research and development centers around the world.

For more information, please visit www.essilor.com.

The Essilor share trades on the NYSE Euronext Paris market and is included in
the EuroStoxx 50 and CAC 40 indices.

Codes and symbols: ISIN: FR FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

Investor Relations and Financial Communications
Phone: +33 (0)1 49 77 42 16 

Copyright Business Wire 2013